NCX 4251

Nicox Ophthalmics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	NCX 4251
Sponsor	Nicox Ophthalmics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis (PHASE2)
Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NCX 4251 CI brief — competitive landscape report
NCX 4251 updates RSS · CI watch RSS
Nicox Ophthalmics, Inc. portfolio CI